Morepen Laboratories logo

Morepen Laboratories financials: balance sheet, profit and loss, cash flow

NSE: MOREPENLABBSE: 500288Pharmaceuticals & BiotechnologySmall Cap

Morepen Laboratories Limited · Face value ₹2 · Listed Mar 1993 on BSE, Nov 1999 on NSE
Last close ₹132.18up ₹6.17 (4.90%)BSE ₹132.50

Share price at the NSE close on 27 Oct 2026. Previous close ₹126.01.

27 Oct: open ₹129.00, high ₹132.31, low ₹127.55

52-week range of traded prices to 27 Oct 2026
₹33.05Low, 30 Mar 2026₹150.70High, 7 Oct 2026
Market cap
₹7,243 Cr1,108th largest listed
P/E
38.41
P/B
5.24
Dividend yield
0.15%
ROE
14.6%
ROCE
14.3%
Debt to equity
0.22
Volume, NSE
76,16,413

Morepen Laboratories' financial statements for the 10 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them.

10 years at a glance

₹ crore, years to March.Morepen Laboratories annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
58424Mar 1760730Mar 187692911Mar 198533412Mar 201,1889716Mar 211,54710219Mar 221,4183925Mar 231,6909629Mar 241,81211879Mar 251,80695195Mar 26
Peak revenue ₹1,812 Cr, year to Mar 2025; lowest ₹584 Cr, year to Mar 2017

Operating and net margin, per cent

  • Operating margin
  • Net margin
10.7%2.7%10.4%10.7%8.8%8.0%10.0%8.8%5.6%9.4%9.6%7.0%4.0%4.9%3.8%3.9%8.2%6.6%2.7%5.7%6.5%5.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 14.8% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue1,806
  2. Materials and goods−1,123
  3. Employee costs−233
  4. Other expenses−324
  5. Operating profit126
  6. Depreciation−36
  7. Other income+21
  8. One-off items+26
  9. Finance costs−16
  10. Profit before tax120
  11. Tax−24
  12. Joint ventures−0.8
  13. Net profit95

What the company owns

  • Plant, investments and other assets₹1,239 Cr
  • Receivables₹333 Cr
  • Inventory₹272 Cr
  • Cash and bank₹69 Cr
  • Current investments₹23 Cr

What pays for it: net worth and liabilities

  • Net worth₹1,247 Cr
  • Owed to suppliers₹317 Cr
  • Borrowings₹195 Cr
  • Other liabilities₹177 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Morepen Laboratories quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 12 MayMar 2026Sep 2026Twelve monthsFiled 27 Oct
Revenue from operations5846077698531,1881,5471,4181,6901,8121,8062,286
5235427017851,0701,4101,3381,5321,6381,6802,009
Materials and goods bought3633694965577811,0499561,0621,1591,1231,304
Employee costs––95110136164155181209233263
Other expenses––109117153197228288269324442
Operating profit before depreciation6165686911913780159174126276
Operating margin10.4%10.7%8.8%8.0%10.0%8.8%5.6%9.4%9.6%7.0%12.1%
Materials, % of revenue––64.6%65.3%65.7%67.8%67.4%62.8%64.0%62.2%57.1%
Employee costs, % of revenue––12.4%12.9%11.4%10.6%10.9%10.7%11.5%12.9%11.5%
Other expenses, % of revenue––14.2%13.7%12.9%12.7%16.1%17.0%14.9%17.9%19.3%
Depreciation and amortisation3434403730282833293635
Operating profit after depreciation27302832881095212514589242
Other income44491210614182126
Finance costs74222−72481618
Profit before one-off items and tax24302939991275613515594250
One-off items000000000260
Profit before tax243029399912756135155120250
00061251739372461
Share of profit of joint ventures and associates––0000000−10
Net profit2430293497102399611895189
Other comprehensive income––−2−300−1−2067
Total comprehensive income––2731971013794118101196
Net margin4.0%4.9%3.8%3.9%8.2%6.6%2.7%5.7%6.5%5.3%8.2%
Net margin without joint ventures and associates––3.8%3.9%8.2%6.6%2.7%5.7%6.5%5.3%–
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2017 and Mar 2018 they do not, so they are left blank.

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 12 MayMar 2026Sep 2026Half yearFiled 27 Oct
2532844245787528471,1871,2471,382
2532844255797538471,1561,2461,381
Share capital90909096102102110110110
Reserves1631943354836517451,0471,1371,272
Belonging to outside owners of subsidiaries0000003111
11121619252979195305
339351404456321402501490726
23283035374490199198
Total assets6156638581,0701,1101,2931,7781,9362,306
316291331336354404619773866
2993725277347568891,1591,1641,440
Net debt−21−27−52−27−31−23−4810334
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 12 MayMar 2026Sep 2026Half year
51−58−91733233127
52−33−751116958173
−78−182−160−61−123−114−46
Receivables−44−69−13−620−50−11
Inventories−37−10147−20−5118−52
Payables00000−250
Other working capital3−13−19521−72−5717
Tax paid−1−25−17−38−37−25−46
Capital spending224536711248665
Free cash flow29−103−1272−92−5363
−70−32−47−83−322−123−105
4764144530097102
Dividends paid000001111
Shares bought back0000000
Shares issued053137019100
Net change in cash28−266−5107124
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Morepen Laboratories dividend history

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 12 MayMar 2026
Earnings per share₹0.51₹0.66₹0.64₹0.75₹2.16₹2.26₹0.77₹1.88₹2.20₹1.73
Diluted earnings per share₹0.51₹0.66₹0.64₹0.75₹2.15₹1.96₹0.77₹1.88₹2.20₹1.73
Dividend per share––––––––₹0.20₹0.20
Book value per share––₹5.63₹6.32₹9.44₹12.11₹14.73₹16.58₹21.10₹22.75
Dividend payout––––––––9.3%11.6%
Shareholder yield––––0.0%−3.2%−10.4%0.0%−7.3%0.6%
Market cap at the year end (₹ crore)8551,3857764301,4441,6441,3192,1492,6211,846

Ratios

Consolidated, years to March.Morepen Laboratories PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Filed 12 MayMar 2026
Revenue growth–3.9%26.7%11.0%39.3%30.2%−8.4%19.3%7.2%−0.3%
Operating profit growth–6.3%4.3%1.5%73.0%15.3%−41.8%99.4%9.7%−27.8%
Net profit growth–25.7%−2.5%16.4%189.1%4.7%−62.0%148.6%22.7%−19.6%
Earnings per share growth–29.4%−3.0%17.2%188.0%4.6%−65.9%144.2%17.0%−21.4%
––11.4%12.5%27.4%20.3%5.8%12.0%11.8%7.9%
–––1.1 pts14.9 pts−7.1 pts−14.5 pts6.2 pts−0.2 pts−3.9 pts
From the net margin–––0.6 pts13.5 pts−5.4 pts−11.9 pts6.3 pts1.7 pts−2.3 pts
From asset turnover–––0.8 pts4.4 pts0.6 pts−1.6 pts1.0 pts−2.2 pts−1.7 pts
From borrowing–––−0.3 pts−3.0 pts−2.4 pts−1.0 pts−1.1 pts0.2 pts0.1 pts
Return on capital employed––10.5%10.7%20.0%18.3%6.6%14.3%11.5%6.2%
Cash conversion––––52.5%−56.8%−235.7%76.3%27.2%34.4%
Interest cover3.87.013.115.949.3−14.826.133.717.45.4
Debt to equity––0.040.040.040.030.030.030.070.16
Receivable days––6459565968706567
Inventory days––6991829687859488
Payable days––124113989087101114103
Cash conversion cycle, days––937406569544553
Working capital days––−30−3225910499118130
Asset turnover––1.251.331.561.601.301.411.180.97
Assets per rupee of net worth––2.432.382.151.921.641.501.531.55
Sales per rupee of plant––5.226.369.1910.558.497.935.724.74
Capital spending to depreciation––––0.721.641.282.134.282.35
Plant being built, % of plant in use––0.0%0.0%1.5%9.6%10.2%11.5%9.0%5.7%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
5.1%
Cash from operations against operating profit
26.0%
Measure10 years5 years3 years
Revenue growth, yearly rate–8.7%8.4%
Profit growth, yearly rate–−0.5%34.9%
Return on equity, average–11.6%10.6%
Return on capital employed, average–11.4%10.6%
Operating margin, average8.8%8.1%8.7%
Net margin, average5.2%5.4%5.8%
Asset turnover, average–1.291.19
Cash conversion cycle, days, average–5751
Interest cover, average15.713.618.9
Debt to equity, average–0.060.09

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−1113833
Cash from investing−606−528−123
Cash from financing61040297
Capital spending36228186
Dividends paid111111
Shares bought back000
Shares issued for cash3801910
Borrowings raised193186132
Borrowings repaid181616

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––734645
Altman Z-scorePublished threshold 1.81––3.002.624.494.894.955.815.254.01
Beneish M-scorePublished threshold −1.78––––−1.86−1.46−1.82−2.33−2.10−2.43
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––15.3119.8216.188.8326.5310.00
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––−0.41−0.320.060.45
Receivables growth less revenue growthOur threshold 0 percentage points–––−8.06−7.097.5313.394.18−7.222.90
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––34.73−13.4222.90−8.11−2.5511.55−6.28
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––2.103.753.893.243.307.943.30
Assets under construction, years of additionsOur threshold 2 years of additions–––0.000.080.310.350.310.210.21
Effective tax ratePublished threshold 17.16 per cent0.000.001.1514.141.4419.7530.6328.6523.9120.24
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––0.070.940.50−0.04−0.84
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
22 Aug 2025Infomerics Valuation and Ratings Private LimitedLong Term Bank FacilitiesIVR A-New, NewStable225
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.